In This Issue

When Is a Monobloc Not a Monobloc? Cautions for Clinical Practice
Dort

Managing Sub-Optimal Responders through Combination Therapy
Bell

Does CPAP Pressure Predict Treatment Outcome with Oral Appliances?
Dort, Savard, Dort, Dort, Dort

Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnoea (PROMAD): Study Design and Baseline Characteristics
Verbruggen, Vroegop, Dieltjens, Wouters, Kastoer, De Backer, Verbraecken, Willemen, Van de Heyning, Braem, Vanderveken
EDITORIALS

109
When Is a Monobloc Not a Monobloc? Cautions for Clinical Practice
Leslie C. Dort

111
Managing Sub-Optimal Responders through Combination Therapy
Gordon M. Bell, DDS

ORIGINAL ARTICLES

113
Does CPAP Pressure Predict Treatment Outcome with Oral Appliances?
Leslie C. Dort, Nicole Savard, Erika Dort, Malcolm Dort, Joseph Dort

119
Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnoea (PROMAD): Study Design and Baseline Characteristics

LETTERS TO THE EDITOR

139
Practices that Can Impact Proper Assessment of the Upper Airway Volume
Ahmed I. Masoud

141
Anatomical and Functional Factors that Interfere with the Syndrome of Obstructive Apnea Recurrent Sleep in Children Aged 7 to 14 Years and the Importance of CTCB for the Recognition of Factors
Response to Masoud
Rosa Carrieri Rossi

NEWS AND UPDATES

143
AADSM 2016 Educational Calendar of Events
AADSM Staff
The authors of the recently published *Journal of Clinical Sleep Medicine* manuscript that compared mandibular advancement device (MAD) and nasal continuous positive airway pressure (CPAP) treatment outcomes are to be commended for their contribution to the area of MAD therapy. Their findings strengthen the evidence for positional obstructive sleep apnea (P-OSA) as a clinical predictor for MAD therapy outcome. The finding that MADs are as efficacious as CPAP in those with P-OSA supports the expanding use of MADs in the treatment of obstructive sleep apnea (OSA). This is not the first study to report equivalent outcomes when comparing MAD treatment to CPAP for those with OSA. Hoekema previously reported the findings of a randomized controlled trial demonstrating equivalence of treatment outcome in mild-to-moderate OSA patients without controlling for position. Hopefully, given that compliance with CPAP is poor and likely to be abandoned by patients, more patients will be given the opportunity to receive MAD therapy: an equivalent alternative.

There are concerns with some of the terms used in the manuscript and how they may be interpreted. The authors repeatedly term the appliance used a “monobloc” appliance as opposed to an “adjustable or titratable” appliance. The methods used in this study may mislead readers as to the results likely to be achieved with monobloc appliances. Monobloc appliances are single piece devices fabricated in a fixed, non-adjustable lower jaw position (protrusion). Clinicians expect to fabricate a monobloc MAD at one protrusive position and leave it there for the entire course of treatment until the device is worn out years later.

Titratable or adjustable MADs allow for increases (or decreases) in protrusive position at any time in the course of treatment by incorporating expansion screws or other mechanisms.

The present study by Takaesu et al. effectively turned a monobloc into an adjustable MAD. The MADs in the study were sequentially remade after being cut apart and repositioned at increased protrusive positions as required to achieve optimal outcome.

Many previous MAD studies, supposedly using “monoblocs”, have used similar methodology. These methods can lead to the false conclusion that monobloc MADs are equivalent to adjustable MADs in treating OSA. This conclusion in turn may lead to inadequate treatment of patients when clinics cannot duplicate the research procedures. Monoblocs in clinical practice are not cut apart sequentially and repositioned. This practice would be prohibitive in terms of clinician time and laboratory expense. It is only feasible under research conditions.

The cost of a clinical process using monobloc MADs repeatedly remade at increasing protrusive position is likely to be more than that employing an adjustable device. Thus the suggestion that a monobloc is a cost-effective alternative is misleading. The conclusion that an effective appliance is custom-made and titratable (adjustable) remains.

While the authors have contributed to the field demonstrating equivalent outcomes achieved comparing MAD to CPAP treatment, the findings do not contradict the clinical guideline recommendation that “When oral appliance therapy is prescribed by a sleep physician for an adult patient with obstructive sleep apnea, we suggest that a qualified dentist use a custom, titratable appliance...”

**CITATION**


**REFERENCES**


**DISCLOSURE STATEMENT**

Dr. Dort is Editor-in-Chief of the *Journal of Dental Sleep Medicine.*
Managing Sub-Optimal Responders through Combination Therapy

Gordon M. Bell, DDS
York Dental Sleep Therapy, Hellam, PA

One of the more significant challenges faced by all who have provided oral appliance therapy (OAT) for any length of time is how to deal with the sub-optimal responder. Despite valiant best attempts at providing therapeutically effective treatment, many of our patients have either excessive residual apnea-hypopnea indexes (AHIs) or residual symptoms at the point of maximum appliance titration. It is not our fault, not the patients’ fault, and not the fault of our appliances. The simple fact is that the make-up of some patient’s disorders is such that there is not a one solution answer for their therapy. It has become apparent over time that in many instances it is necessary to combine therapies to come up with an effective management solution for some of our more resistant patients. It is very common to combine OAT and positional therapy, surgery, or positional therapy. This article will focus on the combined utilization of OAT with continuous positive airway pressure (CPAP) therapy.

Many patients come to us after they have been non-receptive or non-responsive to prior CPAP therapy. Many of these patients fail therapy due to issues related to complications from excessive pressure. The pressure necessary to effectively ventilate some patients is beyond their ability to cope with the resultant side effects. Through the use of a combination of OAT and positive airway pressure (PAP) therapy, it may be possible to manage a large number of our patients who were sub-optimal responders to OAT.

The principal challenge in providing combination therapy is the simple fact that we are not able to predict for which patients we will need to utilize it. Consequently, a policy of discussing this issue with all patients prior to instituting OAT should be considered. The patient should be informed that a best attempt will be made to manage their disease process via the oral appliance. If, however, their response to therapy is inadequate, they are informed that a combination solution for their disease management will be suggested. Patients are often far more accepting of this necessity if they have been advised of it in the beginning.

Given that a percentage of patients are likely to need combination therapy, the choice of appliance design becomes significant as some appliance designs lend themselves more readily to combination use. The intake procedure should include a discussion of the patient’s prior attempts at PAP therapy and what challenges or issues they encountered. Included in this interaction is a discussion regarding what interface the patient’s prior PAP device utilized. If the patient previously wore a nasal interface, pillows, or mask, consider an oral appliance that provides either for mounting of a nasal armature or at a minimum provides for a “locked” bite to minimize the need for a chin strap. If the patient presents a history of being an obligate mouth breather and had previously used a full face mask, consider using an appliance that provides for an open anterior architecture and an “unlocked” bite. In many instances with an open appliance, if combination therapy becomes necessary, posterior occlusal pads can be provided to slightly open the vertical and provide more freeway space in the anterior. By starting with the end in mind and selecting the oral appliance with combination therapy as a possible end necessity, the practitioner is far less likely to have a situation where the appliance is rendered inappropriate by the need to integrate with pressure therapy.

It is crucial that the treatment outcomes of appliance therapy be adequately quantified. Whether through the use of multi-night nocturnal oximetry, home sleep test (HST) or polysomnography (PSG), it is crucial that the effectiveness of the appliance be established. Using the AADSM guidelines for effective management, if the patient has residual AHI in excess of half of pre-treatment AHI or above 10, the patient is advised that a sub-optimal result has been obtained and combination therapy is recommended. If the patient is receptive to considering this treatment regimen they are referred back to the sleep physician or the sleep lab with a request for a PAP titration study in the presence of the oral appliance. It is at this point that the need for accurate and concise communication with the other professionals becomes tantamount. It is crucial that all parties understand that the oral appliance has been maximally titrated and is being used in this mode to reduce the airway resistance for this patient to hopefully permit lower effective pressure on the PAP device. Used in this manner, significant reductions in PAP pressures may be routinely obtained. These reductions in pressure need will often result in a much greater likelihood of the patient tolerating PAP therapy.

Recently a new approach to combination therapy involving the use of automatic positive airway pressure (APAP), in lieu of in-lab PSG or HST, for the titration component has been utilized. There is increasing pressure from third party payors to reduce utilization costs and make diagnostics more approachable for a greater number of patients. In this mode, the patient merely wears the dental appliance with the APAP and the titration is managed via the pressure algorithms built into the unit. The data stream is then available for the sleep physician to interpret and access what pressure parameters to use for each patient. The upside of this approach is obvious in regards to the cost savings for reduced need for in-lab studies and HSTs. Additionally it could be postulated that the larger sample size as a function of more nights of data may in fact lead to a more representative picture of the patient’s condition.
It is quite possible that we are very likely going to see a greater dependence on remote data collection of this type as the sophistication and reliability of the units improves. It certainly behooves us to find ways to adapt our treatment modalities to successfully interface with these newer treatment modes. The future success of dental professionals in this arena depends on our ability to be nimble and adapt to new technologies as they emerge.

CITATION

Does CPAP Pressure Predict Treatment Outcome with Oral Appliances?

Leslie C. Dort, DDS1; Nicole Savard, RT2; Erika Dort, MSc3; Malcolm Dort, BSc2; Joseph Dort, MD1

1University of Calgary, Calgary, AB, Canada; 2Calgary, AB, Canada; 3University of Victoria, BC, Canada

INTRODUCTION

Obstructive sleep apnea (OSA) is a common condition characterized by repetitive narrowing and collapse of the pharynx during sleep. Pharyngeal narrowing creates substantial reduction in airflow (hypopnea), and pharyngeal collapse results in cessation of airflow (apnea). These interruptions in breathing disrupt blood gases leading to hypercapnic and hypoxic conditions. OSA is associated with significant comorbidities including cardiovascular disease, stroke, and early mortality. The quality of life impact of OSA includes excessive daytime fatigue, unrefreshing sleep, impaired cognition, and increased risk of motor vehicle accidents.

Mild to moderate OSA is present in up to 17% of adults, and severe OSA occurs in at least 6% of adults. Obesity, age, and sex are important risk factors for OSA, and the prevalence of OSA is expected to rise with the rising prevalence of obesity.

The recommended treatments for OSA are continuous positive airway pressure (CPAP) and oral appliances (OA). Optimal CPAP pressure is the pressure that will maintain an open airway in all sleep position and sleep stages. While CPAP has been shown to be effective for those who choose to use it, adherence to treatment is poor. When adherence is defined as a minimum of 4 hours use a night, 46% to 83% of subjects are non-adherent to CPAP. OAs are the first choice alternative to CPAP. In randomized trials comparing CPAP to OAs, patients generally preferred OAs: however, OAs are less effective than CPAP in reducing the apnea-hypopnea index (AHI). There is growing evidence that OAs improve both the symptoms of OSA and the physiologic impacts such as cardiac function and hypertension. The application of OAs in the treatment of OSA is restricted by the limited reliability of predicting outcome with their use. As OAs must be custom made for each individual patient, a trial period or rental period is not possible as it is with a CPAP machine. There is therefore a need to predict which patients will have a favorable treatment outcome with OAs. As many patients have a period of CPAP prior to therapy with an OA, their optimal or effective CPAP pressure is known. Effective CPAP pressure is known to increase with both severity of OSA and obesity, and the effectiveness of OAs is less predictable with severity of OSA and obesity. Two recent studies have investigated the association between CPAP pressure and OA outcome. Tsuikil investigated effective CPAP pressure as a predictor of OA outcome in 35 non-obese Japanese males with severe OSA who had been using of CPAP for an average of 9 months. In this group a CPAP pressure > 10.5 cm H2O was predictive of poor response to OA therapy. Sutherland explored effective CPAP pressure as a predictor of OA outcome in a cohort of 78 Australian, predominantly male, overweight subjects who were treated with both OAs and CPAP in a randomized crossover trial. A CPAP pressure of 13 cm H2O was found to be predictive of OA non-response. The above studies each used a single but different OA design.

http://dx.doi.org/10.15331/jdsm.6248
Table 1—Patient characteristics.

<table>
<thead>
<tr>
<th>Variable</th>
<th>n</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (F/M)</td>
<td>120</td>
<td>35/85</td>
</tr>
<tr>
<td>Age (years)</td>
<td>120</td>
<td>53.0 (9.9)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>85</td>
<td>30.3 (5.0)</td>
</tr>
<tr>
<td>Epworth Sleepiness Scale score</td>
<td>109</td>
<td>10.6 (5.1)</td>
</tr>
<tr>
<td>BL RDI Average (events/h)*</td>
<td>120</td>
<td>25.6 (18.7)</td>
</tr>
<tr>
<td>BL RDI Supine (events/h)²</td>
<td>82</td>
<td>32.9 (22.1)</td>
</tr>
<tr>
<td>BL O₂ Average (%)³</td>
<td>101</td>
<td>92.6 (1.9)</td>
</tr>
<tr>
<td>BL O₂ min (%)⁴</td>
<td>102</td>
<td>77.9 (7.1)</td>
</tr>
<tr>
<td>BL % O₂ time &lt; 90%(% of test time)*</td>
<td>95</td>
<td>11.9 (14.5)</td>
</tr>
<tr>
<td>CPAP 90% Pressure (cm H₂O)¹</td>
<td>120</td>
<td>9.7 (2.3)</td>
</tr>
</tbody>
</table>

*Baseline RDI average events/hour of test time.  
²Baseline RDI supine average events/hour of test time.  
³Baseline oxygen average oxygen saturation.  
⁴Baseline minimum oxygen saturation.  
⁵Baseline percent of test time at < 90% oxygen saturation.  
¹Effective CPAP pressure: pressure the machine was at or below 90% of the time it was in use.

A typical dental sleep medicine clinical practice will include patients treated with a variety of oral appliance designs. It is common for those seeking oral appliance therapy to have had a CPAP trial but less common for them to be long-term CPAP users. The objective of this study is to explore the generalizability of the association between optimal CPAP pressure and the outcome of OA therapy in clinical practice where patients are treated with a variety of OA designs and have had at least a CPAP trial.

**METHODS**

The protocol was approved by the Conjoint Health Research Ethics Board of the Faculty of Medicine at the University of Calgary. This retrospective study included all patients in the private clinical practice of one of the authors (LD) from 2004 until 2012 who had a posttreatment sleep test determining response to oral appliance (OA) therapy and who also had a CPAP trial or who were on long-term CPAP therapy. Patients were excluded if they had upper airway surgery for OSA after baseline sleep testing.

Patients were referred to the clinic for evaluation for oral appliance therapy. Patients were treatment naïve, had failed CPAP, had unsuccessful surgery, or wished to use an oral appliance as alternative therapy when not able to use CPAP.

**Oral Appliance Therapy Protocol**

Patients referred for OA therapy underwent examination and consultation to determine appropriateness for therapy. Patients were excluded if they had too few teeth to retain an appliance, extensive periodontal disease, acute temporo-mandibular joint dysfunction, were in active orthodontic treatment, or had completed orthodontic treatment less than two years previously.

Patients who were appropriate for OA therapy, as limited by the exclusion criteria, and chose to proceed were fitted with one of a number of possible OA designs all with previously established clinical efficacy and FDA 510K acceptance. Adaptation and titration of the OA involved 5–8 clinic visits over a period of 3–5 months. When subjective symptoms had improved or maximum tolerable mandibular advancement was achieved, a follow-up sleep test was conducted. If the first follow-up sleep test indicated suboptimal effect, further mandibular advancement of the device and further testing was conducted until maximum effectiveness was achieved. Patients were then seen for routine follow-up in 6 months and yearly thereafter.

**CPAP Pressure**

Patients had been prescribed a variety of commercially available CPAP machines employing either fixed or auto-titrating capabilities. The effective CPAP pressure was either the fixed pressure at which the machine was set or the 90% pressure in the case of most auto-titrating machines. In the case of auto-titrating machines, the 90% pressure is the setting the machine was at or below 90% of the time it was in use.

**Sleep Testing**

The baseline and outcome sleep testing was conducted with home sleep monitors, type 3 and 4, depending on the monitor used by the referring physician. The respiratory disturbance index (RDI) used is therefore the number of apneas and hypopneas per hour of recording.

**Treatment Response Definitions**

We used the same three definitions of success used in previous studies to facilitate comparisons. The first was a reduction in RDI with the OA to ≤ 5 events/h and a decrease in RDI ≥ 50%. The second was a reduction in RDI to ≤ 10 events/h and a decrease in RDI ≥ 50%. The third was a reduction in RDI ≥ 50%.

**Statistical Analysis**

Statistical analyses were conducted with statistical software (Stata13.1 Statacorp). Independent t-tests and χ² tests were used for continuous and categorical variables, respectively, to compare values before and after OA therapy. Logistic regression was used to identify the best models to predict OAT outcome.

**RESULTS**

The subjects were predominantly male, middle-aged, and overweight individuals with moderate OSA (Table 1). They reported mild sleepiness and the mean CPAP pressure was 9.7 ± 2.3 (± SD) with a range of 5–18 cm H₂O. The CPAP machines were primarily auto-titrating and manufactured by ResMed (Table 2). The mean outcome RDI with an OA was 60% less than the mean baseline RDI. The outcome variables significantly changed compared to baseline were: Average RDI, Supine RDI, minimum O₂, and ESS (Table 3).

Complete response to OA therapy ranged from 34% to 65% of subjects, depending on response criteria (Figure 1). Only within response criterion 1 were there significant differences between responders and non-responders in age, baseline RDI and CPAP 90% pressure variables (Table 4). CPAP pressure was lower for responders versus non-responders by criteria 2 and 3 but was not statistically significant.
Table 2—CPAP delivery methods.

<table>
<thead>
<tr>
<th>Pressure Delivery, n (%)</th>
<th>Auto-Titrating</th>
<th>Fixed Pressure</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>n (%)</td>
<td>86  (72)</td>
<td>9   (7)</td>
<td>25 (21)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Manufacturer, n (%)</th>
<th>ResMed</th>
<th>Fisher-Paykel</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>84 (70)</td>
<td>4 (3)</td>
<td>32 (27)</td>
<td></td>
</tr>
</tbody>
</table>

n total = 120.

Table 3—Differences in variables after oral appliance therapy (t-tests).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline, mean (SD)</th>
<th>Outcome, mean (SD)</th>
<th>p value BL vs. Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>RDI Average</td>
<td>25.61 (18.68)</td>
<td>11.07 (10.50)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>RDI Supine</td>
<td>32.18 (20.16)</td>
<td>15.85 (13.34)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>O₂ Average</td>
<td>92.61 (1.93)</td>
<td>92.57 (1.21)</td>
<td>NS*</td>
</tr>
<tr>
<td>Minimum O₂</td>
<td>79.86 (6.77)</td>
<td>82.62 (5.77)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>% time O₂ &lt; 90%</td>
<td>12.00 (14.72)</td>
<td>9.25 (16.65)</td>
<td>NS*</td>
</tr>
<tr>
<td>Epworth Sleepiness Scale score</td>
<td>10.73 (5.07)</td>
<td>7.47 (4.33)</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

*p > 0.05.

Figure 1—Comparison of effective CPAP pressure between responders and non-responders to OA therapy for the three response criteria.

Boxes = 25th–75th percentiles; Line = median; whiskers = 1.5 × interquartile range (IQR); dots = values beyond 1.5 × IQR.

Univariate logistic regression analysis by response criterion 1, using response as the dependent or outcome variable and CPAP pressure as the independent or predictor variable, was able to predict non-response based on CPAP pressure (AUC = 0.64, odds ratio = 1.27, 95% CI = 0.54–0.74, p < 0.02). Table 5 details the univariate regression models for the 3 response criteria.
A cut point, chosen to maximize sensitivity and specificity, of 9 cm of CPAP pressure correctly predicted 65.8% (sensitivity 76%, specificity 46%, positive/negative likelihood ratio 1.42/0.52) of response to OA therapy. A multivariate model that included BMI as well as 90% CPAP pressure correctly classified 74.1% of responders.

**DISCUSSION**

This is to date the largest study exploring the relationship between CPAP pressure and oral appliance outcome. In this study, CPAP pressure was statistically significantly predictive of oral appliance outcome only using the strictest definition of success (RDI < 5 and a reduction from baseline of at least 50%). This finding is in contrast to Sutherland, who found that CPAP pressure was predictive if criteria 2 and 3 were the definitions of response, but not if criterion 1 was the response definition. The differences in study populations and clinical processes may account for the differences. The baseline BMI of the subjects in the present study was 30.5 ± 5.0 kg/m², slightly larger than the subjects in Sutherland’s study (29.1 ± 5.8 kg/m²) and significantly larger than those in the Tsuiki study (median 26 kg/m²). Fifty percent of the subjects in the present study were not tolerant of CPAP. This is in contrast to the previous studies. Those in the Tsuiki study were tolerant of CPAP for at least three months prior to fabricating the oral appliance. Those in the Sutherland study had a month adaptation to CPAP prior to the study. Possibly the previous experience of failure with CPAP influenced the outcome with the OA in the present study. The percentages of responders to OA therapy by criteria 1, 2, and 3 were 34.2%, 50.0%, and 65.0%. This response is similar to that found by Tsuiki (29%, 40%, and 63%) but less than response in the Sutherland study (53%, 69%, and 80%). Subjects in the present study were diagnosed and evaluated by level 3 or 4 sleep test. This protocol did not change over the study period. The previous studies used PSG for diagnosis and outcome evaluation. Although the sleep test methods differed, the response criteria were the same for all studies. Ours was a retrospective study of clinical patients who had chosen oral appliance therapy over CPAP, in addition to CPAP, or who were intolerant of CPAP. Patients used a variety of oral appliance designs over a longer clinical period than in the previous clinical studies Tsuiki found a significant relationship between CPAP pressure and all 3 response criteria in a smaller study of less overweight Japanese subjects. Tsuiki concluded that a CPAP pressure of 10.5 cm with a sensitivity/specificity of 90/56 was optimal for predicting response to oral appliance therapy. In our study, 9 cm was the optimal cut point, but our sensitivity/specificity (76/46) was considerably weaker.

Differences in the CPAP pressures used could have lead to a variation in results. In our clinical environment many patients were on auto-CPAP and 90% pressures are determined by CPAP downloads. Both previous studies confirmed CPAP pressures with PSG. Sutherland used the 95th percentile rather than the 90th as is routinely used in our clinic. Our study had the additional variation introduced by a multiplicity of CPAP machines and oral appliances whereas in previous studies all patients used the same CPAP and oral appliance design.

The limitations of our study include the retrospective design and the variation introduced by the clinical situation. The patients were evaluated after a variety of acclimation and treatment times and having used a variety of oral appliances and CPAP machines. As the CPAP machines were primarily auto-titrating and by a single manufacturer, it was not possible to do an analysis comparing the results by type of CPAP machine. Despite the limitations of the study, the findings echo the previous studies conducted under more controlled conditions. CPAP pressure is a weak predictor of oral appliance outcome but when combined with BMI can be another clinical tool to help guide treatment decisions.

**Table 4**—Outcomes of oral appliance therapy by response criteria.

<table>
<thead>
<tr>
<th>Response Criteria</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>R1 NR1</td>
<td>41 (10/31)</td>
<td>79 (25/54)</td>
<td>50.0</td>
</tr>
<tr>
<td>R2 NR2</td>
<td>60 (17/43)</td>
<td>60 (18/42)</td>
<td>50.0</td>
</tr>
<tr>
<td>R3 NR3</td>
<td>78 (23/55)</td>
<td>42 (12/30)</td>
<td>50.0</td>
</tr>
</tbody>
</table>

**Table 5**—Univariate logistic regression analyses for prediction of OA non-response with effective CPAP pressure.

<table>
<thead>
<tr>
<th>OA Response Definition</th>
<th>CPAP Pressure Model</th>
<th>SE</th>
<th>p value</th>
<th>Odds Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>χ² = 6.65 p = 0.01</td>
<td>0.12</td>
<td>0.02</td>
<td>1.27</td>
<td>0.90–1.53</td>
</tr>
<tr>
<td>2</td>
<td>χ² = 3.29 p = 0.07</td>
<td>0.10</td>
<td>0.08</td>
<td>1.16</td>
<td>0.98–1.36</td>
</tr>
<tr>
<td>3</td>
<td>χ² = 0.36 p = 0.55</td>
<td>0.09</td>
<td>0.55</td>
<td>1.05</td>
<td>0.90–1.23</td>
</tr>
</tbody>
</table>
There are temporary appliances that can be used during a PSG to predict oral appliance outcomes.\textsuperscript{20,30} The predictive capabilities of these devices is better than CPAP pressure but the additional temporary appliance and PSG add complexity to the process.

Predicting outcomes with oral appliances continues to be a challenge. Many patients present for oral appliance therapy having had a trial of CPAP and clinicians can use information from CPAP trials. CPAP pressure is associated with but does not appear to be a reliable predictor of OA outcome.

REFERENCES


ACKNOWLEDGMENTS

The authors thank Richard Hemming for help with database development.

SUBMISSION & CORRESPONDENCE INFORMATION

Submitted for publication August, 2015
Submitted in final revised form June, 2016
Accepted for publication August, 2016
Address correspondence to: Leslie Dort, DDS, 2716-7th Ave NW, Calgary, AB Canada T2N 1A7; Tel: (403) 686–4339; Fax: (403) 202-0266; Email: lcdort@gmail.com

DISCLOSURE STATEMENT

This was not an industry supported study. Dr. Leslie Dort is Editor-in-Chief of the \textit{Journal of Dental Sleep Medicine}. The authors have indicated no financial conflicts of interest.
Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnoea (PROMAD): Study Design and Baseline Characteristics

Annelies E.R. Verbruggen, MD1,6; Anneclaire V.M.T. Vroegop, MD, PhD1,6; Marijke Dieltjens, MBS, PHD1,2,6; Kristien Wouters, PhD3; Chloé Kastoer, MD1,6; Wilfried A. De Backer, MD, PhD1,3,4,6; Johan A. Verbraecken, MD, PhD1,3,4,6; Marc Willemen, Eng3; Paul H. Van de Heyning, MD, PhD1,3,6; Marc J. Braem, DDS, PhD2,6; Olivier M. Vanderveken, MD, PhD1,3,6

1Antwerp University Hospital, ENT Department and Head and Neck Surgery, Edegem, Antwerp, Belgium; 2Antwerp University Hospital, Department of Special Dentistry Care, Edegem, Antwerp, Belgium; 3Antwerp University Hospital, Multidisciplinary Sleep Disorders Centre, Edegem, Antwerp, Belgium; 4Antwerp University Hospital, Department of Pulmonary Medicine, Edegem, Antwerp, Belgium; 5Antwerp University Hospital, Department of Scientific Coordination and Biostatistics, Edegem, Antwerp, Belgium; 6University of Antwerp, Faculty of Medicine and Health Sciences, Edegem, Antwerp, Belgium

Introduction

Obstructive sleep apnea (OSA) is a highly prevalent disease and public health issue, affecting approximately 34% of middle-aged men and 17% of middle-aged women in the United States.1 The condition is characterized by periodic partial or complete obstruction of the upper airway (UA) during sleep, causing sleep fragmentation and hypoxemia.2 The severity of OSA is expressed in terms of the number of apneas and hypopneas per hour of sleep, the apnea-hypopnea index (AHI). OSA poses a strong and independent risk factor for cerebro- and cardiovascular morbidity, associated with high rates of morbidity and mortality.1-7

Continuous positive airway pressure (CPAP) is the advised standard of treatment for patients diagnosed with AHI > 15 events/h.8 However, its clinical effectiveness is limited by moderate patient acceptance and tolerance, leading to unsatisfactory compliance.9-11 The most commonly used class of oral appliances, the mandibular advancement device (OAm), is recommended as a first-line therapy for patients with sleep-disordered breathing, having an AHI of up to 15 events/h, and in patients who fail or refuse treatment with CPAP.12 The OAm is worn intra-orally during sleep and maintains the mandible in a protruded position, commonly with a design to additionally protrude the mandible in search for the most effective protrusion.13-15 The aim is to prevent UA collapse during sleep by increasing the cross-sectional pharyngeal area, thereby reducing snoring and OSA.16-19 However, there is a high interindividual variability in success rate with OAm as reported in the literature.20 Optimal prediction of individual treatment outcome, improving the selection of OSA patients for OAm therapy, is therefore desirable from both therapeutic as well as financial perspectives, although it remains an unresolved key issue.
Awake nasendoscopy including Müller manoeuvre as well as drug-induced sedation endoscopy (DISE) can be used to assess the anatomical level at which snoring and pharyngeal collapse with and without mandibular protrusion \(^\text{11}\) will occur as well as the pattern of collapse and anatomical abnormalities. These techniques have been suggested as valuable prognostic indicators of successful OAm treatment in the individual patient. \(^\text{12-24}\)

In the past, UA imaging techniques using a three-dimensional and dynamic approach have been applied to study the pathophysiological aspects of OSA. \(^\text{18,25-29}\) Computer models have been developed according to the principles of computational fluid dynamics (CFD) using transformed data from three-dimensional computer tomography (CT) images of OSA patients. CFD models allow for evaluation of the airflow and the resistance within the pharynx of the individual OSA patient. \(^\text{30,31}\) In previous studies, CFD is suggested as a potential adequate predictive tool for treatment outcome with OAm in OSA patients. \(^\text{32-34}\)

The “PRedicting therapeutic Outcome of Mandibular Advancement Device treatment in obstructive sleep apnea” (PROMAD) trial aims at identifying the predictive power of awake nasendoscopy including Müller manoeuvre, DISE, and CT-scan based CFD in treatment outcome with OAm. Additionally, the effect of the combination of these techniques and their relative weight, in terms of predicting the treatment outcome with OAm therapy, is explored.

**METHODS**

**Design**

The PROMAD-study is a prospective, single-center, cohort study that evaluates 100 eligible OSA patients. The eligibility criteria are summarized in **Table 1**.

A comprehensive characterization of the patients comprises anthropometric data, polysomnography (PSG), awake nasendoscopy including Müller manoeuvre, DISE, and awake UA CT-scan with CFD.

**Table 1—Eligibility criteria.**

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criterion</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Age ≥18 years</td>
<td>• Absolutep dental contraindications:</td>
</tr>
<tr>
<td>• Body mass index (BMI) ≤ 35 kg/m(^2)</td>
<td>- Functional restrictions of the temporomandibular joint</td>
</tr>
<tr>
<td>• OSA as defined by the American academy of sleep medicine task force</td>
<td>- Insufficient dentition with pathological aspects</td>
</tr>
<tr>
<td>Diagnostic criteria: (A + B + D or C + D):(^\text{2})</td>
<td>- Insufficient retention for Respident Butterfly OAm use</td>
</tr>
<tr>
<td>A. Anamnesis [at least one of the following criteria]</td>
<td>• Other sleep disorders (e.g. parasomnias)</td>
</tr>
<tr>
<td>1. Unwanted sleepiness and/or fatigue in the daytime, unrefreshing sleep or insomnia</td>
<td>• Previous invasive UA surgery for sleep-disordered breathing (uvulopalatopharyngoplasty, palatal implants, maxillomandibular advancement, suspension or resection of the tongue base, hyoid suspension, genioglossus advancement)</td>
</tr>
<tr>
<td>2. Nocturnal arousals with breathing stops, gasping</td>
<td>• Genetic disorders with craniofacial and/or UA anomalies</td>
</tr>
<tr>
<td>3. Snoring or breathing stops while sleeping, determined by the bed partner</td>
<td>• Use of benzodiazepine(s) and/or antidepressant(s)</td>
</tr>
<tr>
<td>B. PSG: AHI ≥ 5 events/h of sleep and AHI &lt; 50 events/h of sleep</td>
<td>• Prior history of psychiatric disease (including alcohol abuse)</td>
</tr>
<tr>
<td>C. PSG: AHI ≥ 15 events/h of sleep and AHI &lt; 50 events/h of sleep</td>
<td>• Known history of fibromyalgia or chronic fatigue syndrome</td>
</tr>
<tr>
<td>D. The condition cannot be explained by another sleep disorder, internal or neurological disorder, medication or drug use</td>
<td>• Not willing to participate and/or to give informed consent</td>
</tr>
</tbody>
</table>

Objective baseline evaluation is performed by PSG, and in particular by assessing the AHI. Then treatment is initiated with a titratable custom-made duobloc OAm (Respident Butterfly, Respident, Orthodontic Clinics NV, Antwerp, Belgium). Re-evaluation by PSG with the OAm in situ is performed after 3 months and 1 year after treatment initiation.

Data analysis of the predictive value of awake nasendoscopy including Müller manoeuvre, DISE, and CT-scan based CFD consists of correlating baseline findings without the OAm in situ with changes in AHI following OAm treatment. Moreover the findings of these same investigations with the OAm in situ in 75% of the individual maximal protrusion will be correlated with the therapeutic outcome. Patients as well as investigators assessing the clinical, polysomnographic, and radiological response remain blinded to the data.

The institutional ethics committee has approved the study protocol and written informed consent is obtained from all participants.

**The Mandibular Advancement Device**

A custom-made, titratable, commercially available duobloc OAm with an interconnecting mechanism located in the frontal teeth area allowing for precise adjustment of mandibular protrusion was selected (Respident Butterfly, RespiDent, Orthodontic Clinics NV, Antwerp, Belgium). The appliance consists of two clips (Antwerp DentalClip) (see **Figure 1**), attached to each other via a small screw system located in the frontal teeth area (Nelissen Titrator) allowing for additional gradual titration. The device is set at 75% of the individual maximal protrusion of each patient. The vertical opening, being the distance between the incisal edges of the upper and lower incisors, is kept constant during the treatment on a minimal distance. \(^\text{35}\)

Two temperature-sensitive microsensors with on-chip integrated readout electronics were embedded in the OAm on opposites sides of the maxillary part, to objectively measure...
the therapy compliance (TheraMon, Handelsagentur Gschladt, Hargelsberg, Austria 37–39; and Air Aid Sleep, Air Aid GmbH & Co. KG, Frankfurt am Main, Germany 39) (Figure 1).

**Polysomnography**

A standard full-night PSG is performed (Brain RT software, OSG, Belgium) at baseline to verify the inclusion PSG criteria and to fix the starting point of the study, followed by evaluation after 3 months and after 1 year of OAm therapy. The PSG provides information on respiration, oxygen saturation, and sleep state, as well as on body position, heart rhythm, limb movements and snoring. It comprises recording of respiratory data, including nasal airflow by using an external thermistor, nasal pressure by means of a nasal pressure cannula and respiratory effort through respiratory induction plethysmography. Oxygen saturation is monitored using a pulse oximeter with a finger probe. A microphone qualitatively records snoring, and body position is assessed with a piezoelectric sensor. The PSG includes electroencephalography (EEG), right and left electrooculography, electromyography of the genioglossus muscle and tibialis anterior muscle, and electrocardiography. All sleep records are scored manually according to the American Academy of Sleep Medicine criteria 40 by the same qualified sleep technician. The sleep technician is blinded to the results of the other examinations.

**Assessment of Subjective Complaints and Quality of Life**

Subjective information is collected by digital versions of different relevant questionnaires. The Epworth Sleepiness Scale (ESS) is used to assess excessive daytime sleepiness 41. The visual analogue scale (VAS) for snoring scores the snoring on a scale of 0 (no snoring) to 10 (partner leaves the bedroom). The Functional Outcomes of Sleep Questionnaire (FOSQ) 42 determines the functional status in adults with OSA. The Sleep Apnea Quality of Life Index (SAQLI) 43 questions the OSA-related quality of life. The Pittsburgh Sleep Quality Index (PSQI) 44 assesses sleep quality and disturbances. The Type D Scale-14 (DS14) 45 measures negative affectivity and social inhibition. The NEO-Five Factor Inventory (NEO-FFI 46) explores the five domains of the adult personality. The Short Form Health Survey (SF-36) 47 investigates the patients’ health status. The Beck Depression Inventory (BDI) 48 evaluates mood disturbances.

**Study Protocol**

As illustrated in Figure 2, at T0, patients are screened and complete assessment of the patient status is performed, including medical history, standard ear-nose-throat clinical examination with awake upright nasendoscopy including the Muller manoeuvre and rhinomanometry. The patient is then referred to the dental sleep professional for a general dental examination including an orthopantomography. If the patient meets the eligibility criteria and wants to participate in the PROMAD-study, informed consent is obtained and dental impressions are taken (T1). Different questionnaires, as specified in the previous section, were digitally filled out using touch screen technology.

At T2, a baseline full-night PSG in the sleep laboratory is performed, including lung function testing, arterial blood gas analysis, and a clinical questionnaire as routinely used in the sleep laboratory (see Appendix 1 for the English translated version). In the 19 days prior to the baseline PSG, the patients fill out each day an ESS questionnaire on paper, a sleep diary with the sleeping and waking times, and the PSQI. The day after T2, PSG is followed by a multiple sleep latency test (MSLT) and the start of the OAm therapy upon fitting of the OAm in the 75% protrusive position of the individual patient.

A first follow-up visit is planned 1 month after the start of OAm therapy (T3) and includes a dental checkup with control of the protrusive position at 75%. Subsequently, a low-dose CT scan of the head and neck region is made with and without the OAm in the 75% protrusive position, for CFD analysis including level diagnosis. At this time, subjective information is again collected through digital versions of the following questionnaires: ESS, VAS for snoring, FOSQ, and a clinical
dental questionnaire (see Appendix 2) as routinely used in our multidisciplinary clinic. Between 1 and 3 months after T2, a DISE (T4) is performed with and without the OAm in the 75% protrusive position.

Three months after initiating OAm therapy (T5), a full-night PSG is performed with the OAm in the 75% protrusive position, including lung function testing, arterial blood gas analysis, and the routine clinical sleep questionnaire, as described before. Prior to T5, the patient fills out again the sleep diary and the ESS each day for 19 days, as well as the PSQI. Other subjective information is again collected through digital versions of the following questionnaires: ESS, VAS, FOSQ, SF-36, PSQI, and the routine clinical dental questionnaire. Prior to the PSG, a dental examination is conducted with control of the 75% protrusive position of the OAm. The next day, MSLT, rhinomanometry, and awake nasendoscopy including Muller manoeuvre are performed.

Four weeks after T5, an interdisciplinary visit at the dental and medical outpatient clinic is scheduled (T6) and the results of the PSG evaluation with the OAm are discussed with the patient. From this point on, patients and investigators are not blinded anymore to the results of the investigations. In case the remaining AHI with the OAm in situ is higher than 5 events/hour, the study protocol requires further adjustment of protrusion in order to lower the AHI: the patient is invited to participate in a titration protocol with advancement of the mandible to 90% of the baseline maximal protrusion. The OAm is then fixed in this 90% protrusive position. After a habituation and adaptation period of 2 months, an additional PSG is performed to assess the effect of the 90% protrusive position on AHI (T7).

One year after initiation of treatment a PSG is scheduled in all study patients, with the OAm in either 75% or 90% protrusive position, depending on the patient (T8). Also lung function testing and arterial blood gas analysis are performed. In case of previously pathological MSLT results, the PSG is followed by MSLT the next day. At this time, the patient is also examined by the dental sleep professional to check the condition of the OAm as well as its protrusive position. The questionnaires as on T5 are completed again.

Data collection occurs at screening (T0), at baseline assessment (T2), 1-month follow-up (T3), during DISE (T4), at 3-month follow-up (T5), after titration if needed (T7), and 1 year (T8) after starting therapy. Objective and subjective compliance are verified at T3, T5, and T8.

**Figure 2—Study flow chart of the PROMAD-study.**

**Figure 3—Reasons for non-participation.**

*Medical history, medical contraindications, other complaints, fibromyalgia, no previous PSG available.*
All patients undergo a low-radiation dose CT scan with and without the OAm in situ (T5), a nasopharyngoscopy is performed with a flexible fiberoptic nasopharyngoscope (Olympus END-GP, diameter 3.7 mm, Olympus Europe GmbH, Hamburg, Germany) by a single ENT surgeon and while the patient is awake. At T5, the OAm is removed by the dental sleep professional, allowing assessment of the UA in a baseline setting without any mandibular repositioning, and with a minimal duration of 5 minutes. Thereafter, the dental sleep professional brings the mandible in the maximal protrusive position by pulling it gently forward, also referred to as the chin-lift manoeuvre. This phase lasts for 2 minutes and allows for the observation of the effects of maximal protrusive positioning on the UA collapse patterns.

Awake Nasendoscopy Including Müller Manoeuvre
At screening (T0) and the day after the PSG with the OAm in situ (T5), a nasopharyngoscopy is performed with a flexible fiberoptic nasopharyngoscope (Olympus END-GP, diameter 3.7 mm, Olympus Europe GmbH, Hamburg, Germany) by a single ENT surgeon and while the patient is awake. At T5, the endoscopy is performed with and without the OAm in situ, both in supine and upright position. In each of the 4 phases of this examination, the patient is asked to simulate snoring and to perform a Müller manoeuvre. For this manoeuvre, both nose and mouth are occluded and the patient is asked to inhale maximally. During the awake endoscopy, the degree, the level, and the direction of the collapse pattern. First, the UA dimensions are assessed with the OAm positioned intra-orally during at least 5 minutes with BIS values between 50 and 70. Next, the OAm is removed by the dental sleep professional, allowing assessment of the UA in a baseline setting without any mandibular repositioning, and with a minimal duration of 5 minutes. Thereafter, the dental sleep professional brings the mandible in the maximal protrusive position by pulling it gently forward, also referred to as the chin-lift manoeuvre. This phase lasts for 2 minutes and allows for the observation of the effects of maximal protrusive positioning on the UA collapse patterns.
and the pattern of UA collapse are observed and scored using the same scoring system as during DISE. 23

**Treatment Outcome Measures**

The PROMAD study will explore the predictive value of awake nasendoscopy including Müller manoeuvre, DISE and CFD with and without the OAm in the 75% protrusive position on treatment outcome, determined on T5. For those patients who are unsuccessfully treated at T5, the predictive value of the baseline findings during the investigations will be further analyzed on treatment outcome at T7 with the OAm in 90% protrusion.

Regarding the AHI, several definitions of success can be found in the literature, 38,52–58 with or without requirement for symptomatic improvement. In the PROMAD study, we will analyze the data according to five various definitions of success, shown in Table 3. Since patients are included based on an AHI ≥ 5 events/h, the main definition of treatment response is that “Δ AHI ≥ 50% or AHI < 5 events/h”.

**Data Collection and Statistical Analysis**

Data are stored in Open Clinica (Open Clinica LLC, Waltham, USA, Version: 3.1.4.1), an open source clinical trial software for electronic data capture and clinical data management. Data will be statistically analyzed using R statistical software (R version 3.0.1, R Foundation for Statistical Computing, Vienna, Austria). Descriptive statistics for clinical characteristics of patients will be presented as mean ± standard deviation for continuous, normally distributed variables and median, Q1-Q3 for non-normally distributed variables. Unpaired t-tests will be used to compare baseline measurements between responders and non-responders when data are normally distributed. Nonparametric tests will be used in case the variables are not normally distributed. Categorical variables will be analysed using χ² tests. Multiple logistic regression models will be used to predict response versus non-response based on baseline measurements of the screening procedures correcting for confounding factors. Sensitivity, specificity, and positive (PPV) and negative predictive value (NPV) will be calculated for each of the screening measurements together with their 95% confidence interval. A p value of < 0.05 will be considered statistically significant.

**Sample Size Justification**

To accurately estimate the positive predictive value (PPV), we included 100 subjects in the study. In Figure 5, the precision for the PPV is presented for different response rates with 100 subjects: with a response rate of 50%, we are able to estimate a PPV of 0.5 with a precision (i.e., half width of 95% confidence interval, CI) of 0.125. For a lower or a higher PPV, the precision is improved. Since we expect the response rate to be lower than in studies with a preselected group of patients, 35 a response rate of 50% seems realistic. In case the response rate turns out to be higher, the precision reduces, if the response rate is lower, the precision improves.

This study is not powered to reveal differences in odds for each individual measurement in the screening procedure. Instead our goal is to find a combination of screening measurements that can predict treatment success. Results need to be confirmed in a second trial, which will be powered based on the odds ratios and prevalence rates found in the current study.

**DISCUSSION**

OAm therapy is increasingly used in clinical practice to treat snoring and OSA and has emerged as a valuable alternative for CPAP treatment. The OAm therapy is proven to be efficient in reducing snoring and obstructive breathing events, and it has shown beneficial effects on associated health outcomes such as daytime sleepiness. However, a major issue confronting OAm therapy is that one-third of the patients undergoing such a therapy do not show a beneficial response in terms of reduction in AHI. The inability to adequately and consistently predict treatment outcome potentially results in suboptimal patient selection. Predicting the effectiveness of OAm therapy in the individual patient is a clinical challenge and is important from both treatment and cost-benefit point of view. Ideally the selection procedure has to be accurate, feasible, easily accessible and cost-effective.

However, the search for a predictive model is complicated. First, there are the variety of mechanisms that underlie OSA, such as UA dilator muscle response, ventilator control instability, and anatomic compromise. 39 The interaction between those mechanisms is complex and not yet completely understood. Second, there is the mode of action of the OAm, with both anatomical and functional aspects determining treatment efficacy. The relative contributions of these factors will differ among patients, impeding straightforward prediction of

---

**Table 3**—Treatment response definitions ranged from most liberal to most strict.

<table>
<thead>
<tr>
<th>Definition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Δ AHI ≥ 50%</td>
</tr>
<tr>
<td>2</td>
<td>Δ AHI ≥ 50% or AHI &lt; 5 events/h</td>
</tr>
<tr>
<td>3</td>
<td>Δ AHI ≥ 50% and AHI &lt; 5 events/h</td>
</tr>
<tr>
<td>4</td>
<td>AHI &lt; 5 events/h</td>
</tr>
<tr>
<td>5</td>
<td>Δ AHI ≥ 50% and AHI &lt; 10 events/h</td>
</tr>
</tbody>
</table>

**Figure 5**—Presentation of the precision for the estimation of the PPV for different response rates with 100 subjects.
Therefore, the proof on predictability is still rather limited. Third, a complicating factor is the use of a variety of definitions of treatment success in literature (see Table 3). Treatment success is variously expressed as a reduction in AHI below a specific value or by a percentage reduction in AHI from baseline, with or without requirement for symptomatic improvement. In the PROMAD study, data will be evaluated using different definitions of success (see Table 3). A commonly used surgical criterion of success that is not mentioned in Table 3 is ”Δ AHI ≥ 50% and postoperative AHI < 20 events/h”: the original criterion, however, as published by Sher, was stated as a change in apnea index (AI) or respiratory disturbance index (RDI) of at least 50% and a post-surgery AI below 10 events/h or a post-surgery RDI below 20 events/h. As those parameters currently have become obsolete in describing success, this criterion is not listed in the table. Other commonly used criteria of success not mentioned in our listing are “AHI < 10 events/h.” and ”Δ AHI ≥ 50% or AHI < 10 events/h.” These definitions are not used because they are not suitable to the sample as the inclusion criterion for participation to the study is baseline AHI > 5 events/h. The main definition of treatment response used in the PROMAD study, being ”Δ AHI ≥ 50% or AHI < 5 events/h,” is rather unusual but dictated by one of the main inclusion criteria, namely baseline AHI ≥ 5 events/h.

Previous research, mostly relying on retrospective analysis, showed several anthropometric, polysomnographic, physiologic, and anatomical factors to be associated with OA success (see Table 4). However, those studies lack uniformity, are mostly underpowered, and the results are not always consistent. Furthermore, the indicators of success have often not been tested prospectively, prior to appliance construction. Therefore, the proof on predictability is still rather limited and research is ongoing. In this study, each distinct investigation gives rise to several variables that are prospectively collected and of which the predictive value will be analyzed. For example, for the findings during DISE we will perform an extensive analysis based on the level, the degree, the direction, and specific collapse patterns. A strength of the present study is that data of the investigations are collected in baseline circumstances as well as with the OA in situ in 75% of the maximal individual protrusion. Thus predictability can be investigated in a prospective way, based on baseline findings as well as based on the findings with the OA in situ. In addition, collection of the data from awake nasendoscopy, DISE, and CFD was performed in a blind fashion, meaning that the treating dentist and sleep physician were blinded to the results of the other investigations. As such, included patients were treated with the OA in a fixed degree of protrusion regardless of the results of the investigations.

The screening of possible candidates for the study took a long time as a result of the strict eligibility criteria that caused the exclusion of many patients. However, a rigorous screening is necessary to obtain a homogeneous group of patients to achieve accurate predictive factors, without interaction of confounding factors biasing the study outcome. We had to screen 402 patients during 27 months to include 100 patients in the study who fulfilled all criteria for inclusion and exclusion in the PROMAD trial. The most common reason for exclusion is dental-related pathology as found in 83 patients (20%), including an insufficient number of teeth, periodontal disease, fragile crown and bridge restorations, limited protrusive capacity, and dentition with pathological aspects. It is important to mention that we evaluated this contraindication as a function of the particular type of OA used in this study for which an optimal dentition is required to guarantee adequate retention. Therefore, the absolute rate of dental contraindications for OA in general will be lower than in the present study. Compared to the literature, the present rate of exclusion on dental aspects is clearly lower than the 34% reported earlier in 2002. A history of psychiatric disease or alcohol or substance abuse was found in 17% of the patients (n = 66). A study performed in 6 European countries including Belgium, reported a prevalence of 25% for a lifetime presence of any

<table>
<thead>
<tr>
<th>Table 4—Patients factors, as reported in the literature, with beneficial effect on OA success.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical parameters</strong></td>
</tr>
<tr>
<td>• Younger age</td>
</tr>
<tr>
<td>• Female gender</td>
</tr>
<tr>
<td>• Smaller neck circumference</td>
</tr>
<tr>
<td>• Lower body mass index</td>
</tr>
<tr>
<td>• Lower Mallampati score</td>
</tr>
<tr>
<td><strong>Polysomnographic parameters</strong></td>
</tr>
<tr>
<td>• Lower baseline AHI</td>
</tr>
<tr>
<td>• Supine dependent OSA</td>
</tr>
<tr>
<td>• A successful titration night with remotely controlled mandibular positioner</td>
</tr>
<tr>
<td><strong>Cephalometric parameters</strong></td>
</tr>
<tr>
<td>• Smaller mandibular-hyoid distance</td>
</tr>
<tr>
<td>• Smaller incisor overjet</td>
</tr>
<tr>
<td>• Longer soft palate length</td>
</tr>
<tr>
<td>• Maxillary prognathia</td>
</tr>
<tr>
<td>• Retrogathic mandible</td>
</tr>
<tr>
<td>• Less erupted maxillary molars</td>
</tr>
<tr>
<td>• Larger oropharyngeal cross-sectional area</td>
</tr>
<tr>
<td><strong>Endoscopic parameters</strong></td>
</tr>
<tr>
<td>• Open airway during Muller manoeuvre</td>
</tr>
<tr>
<td>• Improvement of UA patency on MRI after mandibular advancement during Muller manoeuvre</td>
</tr>
<tr>
<td>• Resolution of airway obstruction with manual mandibular advancement during DISE</td>
</tr>
<tr>
<td>• Improvement of the UA patency with the use of a simulation bite in maximal comfortable protrusion</td>
</tr>
<tr>
<td><strong>Functional parameters</strong></td>
</tr>
<tr>
<td>• Lower nasal resistance on posterior rhinomanometry</td>
</tr>
<tr>
<td>• Primary oropharyngeal collapse with upper-airway closing pressure</td>
</tr>
<tr>
<td><strong>Computational fluid dynamics</strong></td>
</tr>
<tr>
<td>• Decrease in airway resistance</td>
</tr>
<tr>
<td>• Enlargement in UA volume</td>
</tr>
</tbody>
</table>


mental disorder, including anxiety disorders, mood disorders, and alcohol dependence.78

In a previous study, we found a prevalence of 18% to 32% of residual excessive sleepiness based on ESS-scores despite successful OAm treatment (AHI < 5 events/h).79 In the PROMAD-study, MSLTs are additionally performed to obtain the prevalence of residual excessive sleepiness in a prospective way and based on objective tests as well. This is performed in a homogenous group of patients without confounding factors such as medical or psychiatric comorbidities and vigilance-influencing medication.

CONCLUSIONS

The PROMAD study prospectively identifies which of the several previously published predictive factors of success with OAm therapy would adequately forecast success of OAm. It is a prospective nonrandomized observational study that evaluates pre-defined baseline parameters for their ability to predict clinical and polysomnographic response to OAm treatment in OSA patients. Given the prospective nature of data in the PROMAD study, we will be able to fully characterize these patients and identify important and potentially new predictive factors for treatment outcome with OAm. The advantages of each of the individual pre-treatment investigations will be combined with the aim of translating it into an optimal selection procedure, leading to an evidence based decision making and targeted treatment of patients with OSA.

ABBREVIATIONS

AHI, apnea-hypopnea index
BDI, Beck depression index
BIS, bispectral index
BMI, body mass index
CFD, computational fluid dynamics
CI, confidence interval
CPAP, continuous positive airway pressure
CT, computer tomography
DISE, drug-induced sedation endoscopy
DS14, type D scale-14
EEG, electroencephalography
ESS, Epworth Sleepiness Scale
FOSQ, functional outcomes of sleep questionnaire
MSLT, Multiple Sleep Latency Test
NEO-FFI, NEO-Five factor inventory
NPV, negative predictive value
OAm, mandibular advancement device
OSA, obstructive sleep apnea
PPV, positive predictive value
PROMAD, predicting therapeutic outcome of mandibular advancement treatment in obstructive sleep apnea
PSG, polysomnography
PSQI, Pittsburgh Sleep Quality Index
SAQLI, sleep apnea quality of life index
SF-36, short form health survey
UA, upper airway
VAS, visual analogue score

REFERENCES


Predictors of OAm Outcome—Verbruggen et al.


ACKNOWLEDGMENTS

The authors are grateful to the administrative and organizational support of Ms. Nadine De Kerpe. Furthermore, we thank the co-workers of the Sleep Laboratory of the Antwerp University Hospital for conducting the polysomnographic examinations.

SUBMISSION & CORRESPONDENCE INFORMATION

Submitted for publication May, 2016
Submitted in final revised form September, 2016
Accepted for publication September, 2016

Address correspondence to: Annelies Verbruggen, Antwerp University Hospital (UZA), Wilrijkstraat 10, 2650 Edegem, Antwerp, Belgium; Tel: +32 3 821 52 21; Fax: +32 3 821 42 71; Email: annelies.verbruggen@uza.be

DISCLOSURE STATEMENT

This was not an industry supported study. This study was funded by a 3-year grant of the Flemish government agency for Innovation by Science and Technology (IWT-090864). Marc Braem and Olivier Vanderveken are promotors of the SomnoMed Research Grant at the University Hospital of Antwerp. Olivier Vanderveken is consultant for Inspire Medical Systems, Nyxoah and Philips Electronics. Paul Van de Heyning and Olivier Vanderveken received research support at the Antwerp University Hospital from Inspire Medical Systems. Olivier Vanderveken has got research support from ReVent and Nyxoah for clinical trials. He received research support in terms of free devices for an RCT with sleep position trainer in 20 patients from Nightbalance NV, Delft, the Netherlands; and he received lecture fees by Inspire Medical Systems, SomnoMed and Nightbalance. Johan Verbraecken received lecture fees from SomnoMed and AstraZeneca and is consultant for Jazz Pharmaceuticals. The other authors have indicated no financial conflicts of interest.
APPENDICES

Appendix 1: Sleep questionnaire as routinely used in the sleep laboratory

NAME: _______________________________ DATE: ________ / ________ / ________

FIRST NAME: _______________________________ SEX: M / F

DATE OF BIRTH: ________ / ________ / ________ AGE: ______________________________

ADDRESS: ___________________________________________________________________________________________

TELEPHONE: HOME: _______________________________ WORK: ______________________________

PROFESSIONAL SITUATION: ____________________________________________________________
(or previous job)

MARTIAL STATUS: single / married / living together

FAMILY DOCTOR (+address): __________________________________________________________________________

_______________________________________________________________________________________________

SPECIALIST: _______________________________ SPECIALTY: _______________________________

REASON FOR REFERRAL TO SLEEP ANALYSIS: __________________________________________________________________________________________

PLEASE ANSWER EACH FOLLOWING QUESTION (circle the right answer)

1) Do you often feel tired during the day?
   0: no 1: yes

2) Are you restless at night?
   0: no 1: yes

3) Do you snore?
   0: no snoring in any given position
   1: intermittent and discrete snoring only when lying on the back
   2: constant and clear snoring only when lying on the back
   3: constant or loud snoring in all positions
   4: socially unacceptable snoring (sleeping together is impossible, disturbing for surroundings)

4) Are you sleepy during the day?
   0: no sleepiness
   1: mild sleepiness present
   2: sleepiness disturbs the daily activities (driving a car, professional,..)
   3: daily activities impossible

Appendix 1 continues on the following page
### APPENDICES (continued)

5) Do you sometimes fall asleep during the day?
   - 0: never
   - 1: < 1× a week
   - 2: > 1× a week
   - 3: daily

6) Do you suffer from morning headaches?
   - 0: never
   - 1: < 1× a week
   - 2: > 1× a week
   - 3: daily

7) Do you suffer from loss of memory?
   - 0: no
   - 1: yes

8) Do you wake up at night after falling asleep?
   - 0: no
   - 1: sometimes When?________________________

9) Do you feel fresh and alert in the morning after awaking?
   - 0: no
   - 1: mostly

10) Do you feel more tired in the morning as opposed to when you go to sleep?
    - 0: no
    - 1: mostly

11) How deep is your sleep; deep or superficial (superficial in case you awaken easily)?
    - 0: deep
    - 1: superficial

12) Has your partner noticed pauses in your breathing while you are asleep?
    - 0: no
    - 1: yes
    
    If yes, specify:
    - 0 when lying on the back
    - 0 in all positions

13) Do you feel anxious at night or do you have breathing problems?
    - 0: never
    - 1: < 1× a week
    - 2: > 1× a week
    - 3: daily

14) Do you sometimes feel unpleasant pins and needles in your legs, which make you move your legs?
    - 0: no
    - 1: yes

15) Does your bedpartner notice any uncontrolled leg movements in your sleep? (e.g. kicking with your legs)
    - 0: no
    - 1: yes

Appendix 1 continues on the following page
APPENDICES (continued)

16) Are you satisfied with your sleep?
   0: no  1: yes
   If not, what is the main problem?
   0 difficulty falling asleep
   0 difficulty sleeping through the night
   0 waking up too early

17) When did your complaints about snoring start?___________________________________

18) Have you gained weight the last few years? Y / N
   _______kg / _______years

19) Have you previously sought help for your snoring problem?
   0: no  1: yes
   If yes, which help or which treatments?_______________________________________________________
   Have these treatments helped you?_____________________

20) Use of alcohol:
   Number of glasses beer and/or wine a week?
   Before :___________
   Now :___________
   Do you use any alcohol before bedtime?
   0: no  1: yes

21) Use of coffee:___________cups of coffee a day (number)

22) Smoking habits:
   - how much do you smoke a day?____________
   - for how many years?_________years
   If you have stopped smoking:
   - Number of years stopped:___________
   - Started smoking at the age of___________
   - Stopped smoking at the age of___________
   - How much did you smoke a day?____________
APPENDICES (continued)

23) Illnesses and operations? (circle the right answer or fill in)

Throat-Nose-Ear:
- extraction of polyps: Y / N
- extraction of tonsils: Y / N
- runny nose: Y / N
- blocked nose: Y / N
- nasal septum deviation: Y / N
- allergies: Y / N

Which:_________________

Heart:
- heart rhythm disorder: Y / N
- myocardial infarction: Y / N
- high blood pressure: Y / N

When:_________________

Lungs:
- chronic bronchitis: Y / N
- asthma: Y / N

Nervosity, depression, overworked? (circle)

Do you have back problems (or in the past)? Y / N

Other illnesses?_______________________________________________________________

Which operations have you got?_________________________________________________

24) Have you ever got a serious traffic accident? Y / N

How many times have you been involved in a traffic accident?______times

How many times in the last year have you been able to just avoid an accident?______times

25) Medication?

Do you regularly use:
- nose sprays Y / N
- puffs for the airways Y / N
- blood pressure medication Y / N
- sleeping pills Y / N

Write down every medication you are taking at the moment:

- ____________________________________________________________
- ____________________________________________________________
- ____________________________________________________________
- ____________________________________________________________

Appendix 1 continues on the following page
### APPENDICES (continued)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>26)</td>
<td>Height:______cm  Weight:_______kg</td>
</tr>
<tr>
<td></td>
<td>Neck size (or size of your shirt):______cm</td>
</tr>
<tr>
<td></td>
<td>Blood pressure:______/______mm Hg</td>
</tr>
<tr>
<td>27)</td>
<td>Libido (sexual drive)</td>
</tr>
<tr>
<td></td>
<td>0: normal 1: less than normal</td>
</tr>
<tr>
<td>28)</td>
<td>How often do you have to go to the toilet at night?______times.</td>
</tr>
<tr>
<td>29)</td>
<td>Concentration problems?</td>
</tr>
<tr>
<td></td>
<td>0: no 1: yes</td>
</tr>
<tr>
<td>30)</td>
<td>Do you suffer from heartburn or a burning sensation after a meal? During the day or at night? (circle)</td>
</tr>
<tr>
<td></td>
<td>0: never 1: &lt; 1× a week 2: &gt; 1× a week 3: daily</td>
</tr>
<tr>
<td>31)</td>
<td>What time do you normally go to bed?<strong><strong>h</strong></strong></td>
</tr>
<tr>
<td></td>
<td>What time do you normally get up?<strong><strong>h</strong></strong></td>
</tr>
<tr>
<td>32)</td>
<td>For the ladies:</td>
</tr>
<tr>
<td></td>
<td>0: I am before menopause 1: I am in menopause (“hot flushes,”…) 2: I am past menopause</td>
</tr>
<tr>
<td>33)</td>
<td>Remarks of spouse:</td>
</tr>
<tr>
<td></td>
<td>__________________________________________</td>
</tr>
<tr>
<td></td>
<td>__________________________________________</td>
</tr>
<tr>
<td></td>
<td>__________________________________________</td>
</tr>
<tr>
<td>34)</td>
<td>Comments, miscellaneous:</td>
</tr>
<tr>
<td></td>
<td>__________________________________________</td>
</tr>
<tr>
<td></td>
<td>__________________________________________</td>
</tr>
<tr>
<td></td>
<td>__________________________________________</td>
</tr>
</tbody>
</table>
APPENDICES (continued)

Appendix 2: Routine dental questionnaire

1. How do you score your health in general?
   Excellent - very good - good - moderate - bad

2. How do you score your oral health in general?
   Excellent - very good - good - moderate - bad

3. Have you had facial pain in the past month (meaning: pain in the face, the temporal region, the jaws, frontal to or in the ear)?
   Yes - No
   >>> If not, go to question 14 <<<

4. a. How many years ago did you experience facial pain for the first time?
   1 - 2 - 3 - 4–5 - 5–7 - 8–10 - >10

   b. How many months ago did you experience facial pain for the first time?
   1 - 2 - 3 - 4–5 - 5–7 - 8–10 - >10

5. Is the facial pain continuously or intermittently present, or was it a one-time occurrence?
   Continuously - intermittently - one-time occurrence

6. Did you ever visit a doctor, a dentist, a chiropractor or any other health professional for the facial pain?
   - No
   - Yes, in the past 6 months
   - Yes, more than 6 months ago

7. How do you score the facial pain that you feel at this moment, on a scale from 0 to 10, with 0 meaning 'no pain' and 10 meaning 'the worst possible pain'?

8. How do you score the intensity of the worst facial pain you experienced in the past 6 months, on a scale from 0 to 10, with 0 meaning 'no pain' and 10 meaning 'the worst possible pain'?

9. How do you score the average intensity of the facial pain you experienced in the past 6 months, on a scale from 0 to 10, with 0 meaning 'no pain' and 10 meaning 'the worst possible pain'? (meaning the usual pain you experienced on moments of pain)

10. What is the approximate number of days in the past 6 months that you could not carry out your normal activities (school, work, housework) due to the facial pain?

11. Score on a scale of 0 to 10 the extent to which the facial pain influenced your daily activities in the past 6 months, with 0 meaning 'no hindrance' and 10 meaning 'not capable of any activity'.

12. Score on a scale of 0 to 10 the extent to which the facial pain influenced your participation in social, recreational and familial activities with 0 meaning 'no hindrance' and 10 meaning 'not capable of any activity'.

13. Score on a scale of 0 to 10 the extent to which the facial pain influenced your work (incl. housework) with 0 meaning 'no hindrance' and 10 meaning 'not capable of any activity'.

Appendix 2 continues on the following page
APPENDICES (continued)

14. a. Have your temporal joints ever been locked or fixed, causing your mouth not to fully open or close?
   Yes - No
   
   >>> If not, go to question 15 a <<<

   b. Was this limitation of movement to such an extent that you had difficulties eating?
   Yes - No

15. a. Do the joints make a clicking or popping sound when opening or closing the mouth or during chewing?
   Yes - No

   b. Do the joints make a scraping or grinding sound when opening or closing the mouth or by chewing?
   Yes - No

   c. Have you ever been told or are you aware of the fact that you grind your teeth or clench the jaws when you are asleep?
   Yes - No

   d. Do you grind the teeth of clench the jaws during the day?
   Yes - No

   e. Do you have painful or stiff jaw muscles in the morning upon awakening?
   Yes - No

   f. Do you hear noises or ringing in the ears?
   Yes - No

   g. Does your bite feel uncomfortable or different than how it normally feels?
   Yes - No

16. a. Do you suffer from rheumatoid arthritis, lupus erythematoses or another systemic joint disease?
   Yes - No

   b. Does any family member suffer from one of the former diseases?
   Yes - No

   c. Have you had or do you have swollen or painful joints, other than the temporal joints?
   Yes - No
   
   >>> If not, go to question 17 a <<<

   d. Was it or is it a persistent pain, during at least one year?
   Yes - No

17. a. Have you recently had an injury in the face?
   Yes - No
   
   >>> If not, go to question 18 <<<

   b. Was the facial pain already present prior to the injury?
   Yes - No

18. Have you suffered from headache or migraine during the past 6 months?
   Yes - No

Appendix 2 continues on the following page
### APPENDICES (continued)

<table>
<thead>
<tr>
<th>Question</th>
<th>Options</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Are you hindered or impeded during chewing by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>b. Are you hindered or impeded during drinking by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>c. Are you hindered or impeded during physical exercise by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>d. Are you hindered or impeded upon eating of hard food by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>e. Are you hindered or impeded upon eating of soft food by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>f. Are you hindered or impeded upon smiling or laughing by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>g. Are you hindered or impeded during sexual activities by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>h. Are you hindered or impeded upon brushing your teeth of cleansing the face by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>i. Are you hindered or impeded upon swallowing by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>j. Are you hindered or impeded upon talking by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>k. Are you hindered or impeded in your usual facial expression by the current problem with the joints?</td>
<td>Yes - No</td>
</tr>
<tr>
<td>20. a. To what extent have you been hindered by headache in the past week, including today?</td>
<td>Not at all - slightly - moderately - quite a bit - extremely</td>
</tr>
<tr>
<td>b. To what extent have you been hindered by chest pain in the past week, including today?</td>
<td>Not at all - slightly - moderately - quite a bit - extremely</td>
</tr>
<tr>
<td>c. To what extent have you been hindered by low back pain in the past week, including today?</td>
<td>Not at all - slightly - moderately - quite a bit - extremely</td>
</tr>
<tr>
<td>d. To what extent have you been hindered by sore muscles in the past week, including today?</td>
<td>Not at all - slightly - moderately - quite a bit - extremely</td>
</tr>
<tr>
<td>e. To what extent have you been hindered by difficulties in breathing in the past week, including today?</td>
<td>Not at all - slightly - moderately - quite a bit - extremely</td>
</tr>
<tr>
<td>f. To what extent have you been hindered by dizziness in the past week, including today?</td>
<td>Not at all - slightly - moderately - quite a bit - extremely</td>
</tr>
</tbody>
</table>

*Appendix 2 continues on the following page*
APPENDICES (continued)

g. To what extent have you been hindered by nausea or stomach problems in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

h. To what extent have you been hindered by a hot-cold feeling in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

i. To what extent have you been hindered by a numbness or tingling anywhere in your body in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

j. To what extent have you been hindered by the sensation of an obstruction in the throat in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

k. To what extent have you been hindered by a sense of physical weakness in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

l. To what extent have you been hindered by a heavy feeling in the arms and legs in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

m. To what extent have you been hindered by difficulties falling asleep in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

n. To what extent have you been hindered by waking up early in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

o. To what extent have you been hindered by a restless or disturbed sleep in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

p. To what extent have you been hindered by unpleasant thoughts or not getting rid of certain thoughts in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

q. To what extent have you been hindered by a loss of libido or not enjoying sexual activities in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

r. To what extent have you been hindered by a lack of energy in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

s. To what extent have you been hindered by suicidal thoughts in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

t. To what extent have you been hindered by a poor appetite in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

u. To what extent have you been hindered by weeping easily in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

v. To what extent have you been hindered by feeling entangled or trapped in the past week, including today?
   Not at all - slightly - moderately - quite a bit - extremely

Appendix 2 continues on the following page
APPENDICES (continued)

w. To what extent have you been hindered by blaming yourself all sorts of things in the past week, including today?
   - Not at all - slightly - moderately - quite a bit - extremely

x. To what extent have you been hindered by feeling lonely in the past week, including today?
   - Not at all - slightly - moderately - quite a bit - extremely

y. To what extent have you been hindered by being upset in the past week, including today?
   - Not at all - slightly - moderately - quite a bit - extremely

z. To what extent have you been hindered by worrying too much about things in the past week, including today?
   - Not at all - slightly - moderately - quite a bit - extremely

aa. To what extent have you been hindered by not being interested in anything in the past week, including today?
   - Not at all - slightly - moderately - quite a bit - extremely

bb. To what extent have you been hindered by a feeling of emptiness in the past week, including today?
   - Not at all - slightly - moderately - quite a bit - extremely

cc. To what extent have you been hindered by feeling desperate about the future in the past week, including today?
   - Not at all - slightly - moderately - quite a bit - extremely

dd. To what extent have you been hindered by thinking about death or dying in the past week, including today?
   - Not at all - slightly - moderately - quite a bit - extremely

e. To what extent have you been hindered by feeling worthless in the past week, including today?
   - Not at all - slightly - moderately - quite a bit - extremely

21. How well do you take care of your general health?
   - Excellent - very good - good - moderate - bad

22. How well do you take care of your oral health?
   - Excellent - very good - good - moderate - bad
LETTERS TO THE EDITOR

Practices that Can Impact Proper Assessment of the Upper Airway Volume

Ahmed I. Masoud, BDS, MS

Department of Orthodontics, Faculty of Dentistry, King Abdulaziz University, Jeddah, Saudi Arabia; Department of Orthodontics, College of Dentistry, University of Illinois, Chicago, IL; PhD candidate, Graduate Program in Neuroscience, University of Illinois, Chicago, IL

Upon reading the title “Differences in Volume and Area of the Upper Airways in Children with OSA Compared to a Healthy Group” by Rossi et al.¹ in the July 2016 issue of the Journal of Dental Sleep Medicine, I was very excited. However, some of that excitement faded after reading the article. In my humble opinion I thought the study had multiple flaws, but I wanted to focus on three major issues:

1. The objective of this research was to “verify the differences in the volume and areas of the UA among children with OSA who have had adenotonsillectomy but continue to have persistent OSA, and a control group of healthy children.” Seeking that, the authors stated that in the study group “all the patients had undergone adenotonsillectomy or had been excluded of having hypertrophic tonsils: but they all had OSA symptoms.” This statement might just need clarification but from what I understand, there were patients with OSA symptoms who have “not undergone adenotonsillectomy” but were included in the study group because the tonsils were not hypertrophic. I hope my interpretation is wrong because if this is true then this causes major flaws:
   a. No definition of hypertrophic tonsils was used. An objective measure such as a standardized palatine tonsillar hypertrophy grading scale could have been used.² Followed by exclusion of subjects with 2+, 3+, and 4+ tonsils.
   b. Simply excluding subjects with hypertrophic tonsils does not exclude subjects with enlarged adenoids. It is true that they are both lymphoid tissues and their sizes should hypothetically be correlated; however, this has not been shown to be the case. Hypertrophic tonsils and adenoids do not necessarily co-exist, and the size of the tonsils cannot be used to predict the size of the adenoids.³⁴ Furthermore, there are surgeons who do not remove the adenoids completely and remnant tissue is left behind, in addition to surgeons who only remove the tonsils and leave the adenoids untouched. This should have been checked on the CBCT.
   c. It contradicts the objective of the article since subjects without adenotonsillectomy were included in the study group.

2. In most anatomical books and papers the nasopharynx “lies behind the nasal cavity above the soft palate.”⁵⁶

The inferior limit in the current article extended far inferiorly that it included the soft palate. Putting that atypical definition aside, the soft palate thickness may increase as a result of vibration or inflammation when snoring.⁷ Since the authors in the current article concluded that “children with persistent OSA symptoms after adenotonsillectomy present with narrowing of the nasopharynx”⁸ and the nasopharynx they used contained the soft palate, the soft palate might have played a role in the persistence of the symptoms in addition to the narrowing of the nasopharynx and should have been discussed.

3. The authors stated that subjects were “placed in the tomography room in a sitting position with their head parallel to the Frankfurt plane.” How can the head be parallel to the Frankfurt plane? An important factor affecting airway analysis is head position.⁹ The method to orient the head should be clearly described.

CITATION


REFERENCES


**SUBMISSION & CORRESPONDENCE INFORMATION**
Submitted for publication August, 2016
Submitted in final revised form September, 2016
Accepted for publication September, 2016

Address correspondence to: Ahmed I. Masoud, Department of Orthodontics, Faculty of Dentistry, King Abdulaziz University, PO Box 80209, Jeddah 21589, Saudi Arabia; Tel: +966503602125; Email: a7moody@gmail.com

**DISCLOSURE STATEMENT**
Dr. Masoud has indicated no financial conflicts of interest.
We thank Dr. Masoud for his important observations regarding our paper. We offer the following response.

The aim of the study was the comparison of the volume and area of the UA with CTCB in healthy and OSA children, diagnosed with polysomnography that is the gold standard for this diagnosis. Therefore we believe that the size of the tonsils is very important but has not been used for the diagnosis of OSA and should not be cited in this study.

The purpose of the study was not to measure the size of the tonsils but the volume of the UA and sites of major constrictions. Recurrence of the clinical condition can happen after adenotonsillectomy, and it is believed to be due to concomitant craniofacial problems, among others. These alterations can be easily recognized and treated by the orthodontist. The inclusion criterion was based on the presence or absence of disease (OSA). The subjects were included or excluded according to their clinical symptoms and according to the results of polysomnography. The age of children was 7–14 years old; this is the age at which regression of lymphoid tissue is expected, especially in those who have undergone surgery.

The study and control groups were formed by the results of this examination and the complaints of patients. The importance of the study was based on detecting locations of lower volume and constriction of the UA. These critical points of constriction can be caused by numerous anatomical and functional factors; knowledge of these factors is essential for professionals involved in research and clinical treatment.

The persistence of disease during growth and development may lead to or exacerbate dental skeletal changes. One of the anatomical factors for persistent OSA can be hypertrophy of the soft palate; therefore we wanted to see areas of constriction in UA. To carry out the tests CTBC, we followed previous studies protocols. As it was a case-controlled study, the measurements were made in both groups in the same way to achieve reliability.

The head of the patient has been positioned according to the recommendations of the CBCT manufacturer, with the Frankfurt plane perpendicular to the floor; that position is guided by a light beam of the device itself, although the head position in CTBC tests can be corrected by software and thus do not interfere with the measurements.

REFERENCES


2. Rossi RC, Rossi NJ, Filho EI, et al. Differences in volume and area of the UA and sites of major constrictions in UA. To carry out the tests CTBC, we followed previous studies protocols. AS it was a case-controlled study, the measurements were made in both groups in the same way to achieve reliability.


**DISCLOSURE STATEMENT**

This was not an industry supported study. The authors have indicated no financial conflicts of interest.

**SUBMISSION & CORRESPONDENCE INFORMATION**

Submitted for publication September, 2016
Accepted for publication September, 2016
Address correspondence to: Rosa Carrieri Rossi, DDS, PhD, Division of Pediatric Otolaryngology, Federal University of Sao Paulo- UNIFESP Brasil, Rua Tijuco preto 1694, Tatuapé São Paulo BR, CEP: 03319000; Tel: 5511 29413629; Email: rosacrossi@gmail.com
NEWS AND UPDATES

AADSM 2016 Educational Calendar of Events

AADSM Staff

AADSM National Office, Darien, IL

October 22
Dental Sleep Medicine Staff Course NEW!
Lombard, IL

November 5–6
Advanced Dental Sleep Medicine Course
Nashville, TN

November 5–6
Essentials of Dental Sleep Medicine Course
Nashville, TN

December 3
Practical Demonstration Course
Darien, IL – AADSM National Office